| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Central Laboratory of the Netherlands Red Cross Blood Transfusion Services and Laboratory for Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, The Netherlands;
Behringwerke AG, Marburg, Germany;
Oklahoma Medical Research Foundation, Oklahoma City, OK 73104; and
§
Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands
We evaluated the effect of C1 inhibitor (C1-inh), an inhibitor of the classical pathway of complement and the contact system, on the physiologic and inflammatory response in baboons suffering from lethal Escherichia coli sepsis. Five animals pretreated with 500 U/kg C1-inh (treatment group; n = 5), followed by a 9-h continuous infusion of 200 U/kg C1-inh subsequent to bacterial challenge, were compared with five controls receiving E. coli alone. Of the treatment group, one animal survived and another lived beyond 48 h, whereas all control animals died within 27 h. In four of five treated animals, less severe pathology was observed in various target organs. C1-inh administration did not prevent the hemodynamic or hematologic changes observed upon E. coli infusion. The activation of fibrinolysis and the development of disseminated intravascular coagulation were essentially unaffected by C1-inh. However, C1-inh supplementation significantly reduced decreases in plasma levels of factor XII and prekallikrein and abrogated the systemic appearance of C4b/c, indicating substantial inhibition of activation of the contact system and the classical complement pathway, respectively. Furthermore, treated animals displayed a reduced elaboration of various cytokines including TNF, IL-10, IL-6, and IL-8. Thus, the administration of C1-inh may have a beneficial but modest effect on the clinical course and outcome of severe sepsis in nonhuman primates. We suggest that activated complement and/or contact system proteases may, at least in part, contribute to the attendant manifestations of septic shock through an augmentation of the cytokine response.
This article has been cited by other articles:
|
|
 |
|
  E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, F. Lu, G. Qin, S. M. Fernandes, J. Li, and A. E. Davis III C1 Inhibitor-Mediated Protection from Sepsis J. Immunol., September 15, 2007; 179(6): 3966 - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zeerleder, C. E. Hack, and W. A. Wuillemin Disseminated Intravascular Coagulation in Sepsis Chest, October 1, 2005; 128(4): 2864 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. van der Poll, M. Levi, J. A. Nick, and E. Abraham Activated Protein C Inhibits Local Coagulation after Intrapulmonary Delivery of Endotoxin in Humans Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1125 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, D. Zhang, J. Scafidi, X. Wu, C. C. Cramer, and A. E. Davis III C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability Blood, March 15, 2005; 105(6): 2350 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, S. Cai, X. Gu, J. Scafidi, X. Wu, and A. E. Davis III C1 Inhibitor Prevents Endotoxin Shock Via a Direct Interaction with Lipopolysaccharide J. Immunol., September 1, 2003; 171(5): 2594 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zeerleder, C. Caliezi, G. van Mierlo, A. Eerenberg-Belmer, I. Sulzer, C. E. Hack, and W. A. Wuillemin Administration of C1 Inhibitor Reduces Neutrophil Activation in Patients with Sepsis Clin. Vaccine Immunol., July 1, 2003; 10(4): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Aird The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Blood, May 15, 2003; 101(10): 3765 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Mollnes, O.-L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation Blood, August 13, 2002; 100(5): 1869 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tapper and H. Herwald Modulation of hemostatic mechanisms in bacterial infectious diseases Blood, October 1, 2000; 96(7): 2329 - 2337. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Minnema, A. C. K. Chang, P. M. Jansen, Y. T. P. Lubbers, B. M. Pratt, B. G. Whittaker, F. B. Taylor, C. E. Hack, and B. Friedman Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood, February 15, 2000; 95(4): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
